Roivant gains after mid-stage trial data for Immunovant’s main asset
Roivant Sciences Ltd. Common Shares · PHARMACEUTICAL PREPARATIONS · Now $29.99
-8.5% in 3d after detection
Post-detection moves
1h
—
1d
-4.7%
3d
-8.5%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS